SCHEDULE: Farallon Amends Lantheus Holdings Stake, Updates Management

Farallon Capital Management updates its beneficial ownership in Lantheus Holdings, Inc. to 8.2% and reports internal management changes.

Summary

• Farallon Capital Management, through various funds and entities, collectively holds 5,427,479 shares of Lantheus Holdings, Inc. Common Stock, representing 8.2% of the class.
• The beneficial ownership is shared among several Farallon funds, including Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Healthcare Partners Master, L.P., and others.
• Farallon Partners, L.L.C., as the general partner for several funds and sole member for others, is deemed a beneficial owner of 5,281,936 shares, or 8% of the class.
• Fifteen individual managing members and senior managing members of Farallon entities are deemed beneficial owners of 5,427,479 shares, or 8.2% of the class, due to their investment discretion.
• Avner A. Husen became a managing member/manager across Farallon entities, effective January 1, 2026, and is now deemed a beneficial owner.
• Richard B. Fried, Rajiv A. Patel, and William Seybold ceased to be managing members/managers across Farallon entities, effective December 31, 2025, and are no longer deemed beneficial owners.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While a routine ownership update, the continued significant stake by a major institutional investor like Farallon Capital Management in Lantheus Holdings, Inc. suggests a sustained positive outlook on the company's value.

Positives

• The continued significant stake by Farallon Capital Management, a prominent institutional investor, may signal confidence in Lantheus Holdings, Inc.'s long-term prospects.

Negatives

• No specific negative information regarding Lantheus Holdings, Inc. was disclosed in this ownership filing.

Risks

• The filing itself does not detail risks specific to Lantheus Holdings, Inc. but rather reports beneficial ownership and internal management changes at Farallon.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Lantheus Holdings, Inc.'s future performance or operations.

Industry Context

StockSavvy.ai notes that institutional ownership updates, particularly from established firms like Farallon Capital Management, are routinely monitored by the market. While this filing primarily details internal changes within Farallon and an updated ownership percentage, the continued significant stake in Lantheus Holdings, Inc. suggests ongoing interest in the healthcare diagnostics and radiopharmaceuticals sector.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for reporting beneficial ownership exceeding 5% of a company's outstanding shares, aligning with industry practices for transparency in institutional investment.
• Farallon Capital Management's 8.2% stake in Lantheus Holdings, Inc. is a substantial position, comparable to significant institutional holdings seen in other mid-cap healthcare and biotech companies, indicating a conviction investment rather than a passive index-tracking position.

Management Changes

Stakeholder Impact

• Shareholders of Lantheus Holdings, Inc. are informed of the continued significant institutional ownership by Farallon Capital Management, which can be interpreted as a vote of confidence in the company's strategy and performance.
• The internal management changes within Farallon Capital Management primarily affect the internal governance and beneficial ownership attribution within the investment firm, with no direct impact on Lantheus Holdings, Inc.'s operations or governance.

Key Dates

Recommendation

This filing is a routine update of beneficial ownership and internal management changes at Farallon Capital Management. It does not contain new information about Lantheus Holdings, Inc.'s financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. The continued significant stake by a major institutional investor is generally a neutral to slightly positive signal, suggesting a 'hold' position for existing investors and no immediate strong 'buy' or 'sell' signal for new investors based solely on this filing.

Keywords

Lantheus Holdings, Farallon Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Shareholder, Investment Management, Healthcare, Biotechnology